Jiangsu Nanfang Medical Co., Ltd. Class A

Jiangsu Nanfang Medical Co., Ltd. Class A

SSSE:603880
5.98
CNY
-0.48
(-7.43%)
-0.36EPS
2.44BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Jiangsu Nanfang Medical Co., Ltd. Class A carries a market capitalization of 2.44B, placing it among publicly traded companies globally. Its enterprise value stands at 2.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.44B
Enterprise Value2.82B

Share Statistics

As of September 30, 2026, Jiangsu Nanfang Medical Co., Ltd. Class A has 289.04M shares outstanding.

Shares Outstanding289.04M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 4.33, and the price-to-book ratio stands at 16.48.

PS Ratio4.33
PB Ratio16.48
P/TBV Ratio22.50

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 5.03 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.82B versus a market cap of 2.44B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.03

Financial Position

As of September 30, 2026, Jiangsu Nanfang Medical Co., Ltd. Class A maintains a current ratio of 0.43, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 279.73, indicating elevated leverage, while an interest coverage ratio of -4.72 demonstrates limited ability to service its debt obligations.

Current Ratio0.43
Quick Ratio0.07
Debt / Equity279.73
Debt / EBITDA-4.42
Interest Coverage-4.72

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Jiangsu Nanfang Medical Co., Ltd. Class A posted a negative return on equity (ROE) of -51.04, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.54, reflecting losses generated across the asset base. The company generates approximately 710,331.06 in revenue per employee across its workforce of 789.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.65 indicates how many times Jiangsu Nanfang Medical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-51.04
Return on Assets (ROA)-11.54
Revenue Per Employee710,331.06
Employee Count789.00
Inventory Turnover3.65

Taxes

CNY

Over the twelve months ended September 30, 2026, Jiangsu Nanfang Medical Co., Ltd. Class A recorded 8.29M in income tax expense. The company reported a pretax loss of -95.67M and -105.79M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax8.29M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Jiangsu Nanfang Medical Co., Ltd. Class A's stock has declined approximately 16.71% over the past 52 weeks. The 50-day moving average sits at 8.56, while the 200-day moving average is 7.58.

52-Week Price Change-16.71%
50-Day Moving Average8.56
200-Day Moving Average7.58

Income Statement

CNY

Over the twelve months ended September 30, 2026, Jiangsu Nanfang Medical Co., Ltd. Class A generated 560.45M in revenue and converted that into -105.79M in net income, yielding earnings per share of -0.36. EBITDA reached -94.87M, while operating income came in at -65.15M.

Revenue560.45M
Gross Profit15.27M
Operating Income-65.15M
Pretax Income-95.67M
Net Income-105.79M
EBITDA-94.87M
EBIT-94.87M
Earnings Per Share (EPS)-0.36

Balance Sheet

CNY

As of September 30, 2026, Jiangsu Nanfang Medical Co., Ltd. Class A holds 42.04M in cash and equivalents against 419.66M in total debt, resulting in a net debt position of 369.58M. Total book value stands at 148.19M, with working capital of -362.03M providing operational flexibility.

Cash & Cash Equivalents42.04M
Total Debt419.66M
Net Debt369.58M
Equity (Book Value)148.19M
Book Value Per Share0.51
Working Capital-362.03M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-18.61M

Margins

Over the twelve months ended September 30, 2026, Jiangsu Nanfang Medical Co., Ltd. Class A posted a gross margin of 2.73, reflecting its pricing power and cost economics. The operating margin of -11.63 and net profit margin of -18.88 provide insight into operational efficiency.

Gross Margin2.73
Operating Margin-11.63
Pretax Margin-17.07
Profit Margin-18.88
EBITDA Margin-16.93

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Jiangsu Nanfang Medical Co., Ltd. Class A paid dividends of 0.08 per share. The dividend payout ratio of -23.77 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.68, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Jiangsu Nanfang Medical Co., Ltd. Class A shareholders.

Dividend Per Share0.08
Payout Ratio-23.77
Shareholder Yield1.68

Stock Splits

Jiangsu Nanfang Medical Co., Ltd. Class A's most recent stock split took place on May 21, 2021 with a 10:13 split ratio.

Last Split Date5/21/2021
Split Ratio10:13

Scores

As of September 30, 2026, Jiangsu Nanfang Medical Co., Ltd. Class A has an Altman Z-Score of 1.49, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.49